Haemonetics (NYSE:HAE) Issues FY 2026 Earnings Guidance

Haemonetics (NYSE:HAE) updated its FY 2026 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 4.800-5.00 for the period, compared to the consensus estimate of 4.820. The company issued revenue guidance of -, compared to the consensus revenue estimate of $1.3 billion.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Mizuho decreased their target price on shares of Haemonetics from $90.00 to $70.00 and set an “outperform” rating for the company in a research note on Friday, August 8th. Raymond James Financial lowered Haemonetics from a “strong-buy” rating to an “outperform” rating and cut their price objective for the stock from $105.00 to $78.00 in a report on Monday, August 11th. JPMorgan Chase & Co. reissued a “neutral” rating and set a $62.00 price objective (down previously from $85.00) on shares of Haemonetics in a research report on Friday, August 8th. Barrington Research boosted their target price on Haemonetics from $86.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday. Finally, Citigroup cut their price target on Haemonetics from $78.00 to $64.00 and set a “buy” rating for the company in a research note on Tuesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $78.50.

Haemonetics Stock Up 2.4%

HAE opened at $68.70 on Friday. The firm has a market cap of $3.31 billion, a P/E ratio of 21.01, a price-to-earnings-growth ratio of 0.91 and a beta of 0.43. The company has a debt-to-equity ratio of 1.04, a quick ratio of 1.04 and a current ratio of 1.72. The business has a 50 day moving average price of $51.53 and a 200 day moving average price of $62.10. Haemonetics has a twelve month low of $47.31 and a twelve month high of $94.99.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.27 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $0.15. Haemonetics had a net margin of 12.14% and a return on equity of 26.64%. The company had revenue of $327.32 million for the quarter, compared to analyst estimates of $311.61 million. During the same quarter last year, the firm posted $1.12 earnings per share. The company’s quarterly revenue was down 5.3% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.800-5.00 EPS. Research analysts forecast that Haemonetics will post 4.55 EPS for the current year.

Institutional Investors Weigh In On Haemonetics

A number of hedge funds have recently bought and sold shares of HAE. Quantinno Capital Management LP increased its holdings in Haemonetics by 9.0% in the 2nd quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock valued at $261,000 after buying an additional 289 shares during the period. Empowered Funds LLC lifted its holdings in shares of Haemonetics by 9.1% during the 1st quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock worth $283,000 after acquiring an additional 372 shares during the period. EverSource Wealth Advisors LLC boosted its position in shares of Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares in the last quarter. Corient Private Wealth LLC increased its stake in Haemonetics by 13.0% in the second quarter. Corient Private Wealth LLC now owns 5,233 shares of the medical instruments supplier’s stock valued at $390,000 after acquiring an additional 600 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Haemonetics by 3.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock valued at $1,877,000 after acquiring an additional 971 shares during the period. 99.67% of the stock is currently owned by institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.